
Novartis, Amgen and Banner Alzheimer’s Institute have dropped a study into investigational Alzheimer’s drug CNP520 (umibecestat) after some patient’s conditions …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

